Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: A randomized controlled study

Diabetes

Volumn 54, Issue 5, 2005, Pages 1459-1467

  Karlsson, Håkan K R ^a   Hällsten, Kirsti ^b   Björnholm, Marie ^a   Tsuchida, Hiroki ^a   Chibalin, Alexander Y ^a   Virtanen, Kirsi A ^b   Heinonen, Olli J ^b   Lönnqvist, Fredrik ^a,c   Nuutila, Pirjo ^b   Zierath, Juleen E ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TURKU   (Finland)

^c BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROLYLTHREONYLASPARAGINYLASPARTYLLYSYLALANYLLYSYLALANYLGLYCYLASPARAGINYLLYS YLPROLINE; PROTEIN; PROTEIN KINASE B; ROSIGLITAZONE; SERINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; EXERCISE; EXOCYTOSIS; FATTY ACID METABOLISM; FEMALE; GENE EXPRESSION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; MALE; MONOTHERAPY; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; METFORMIN; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; THIAZOLIDINEDIONES;

EID: 20944436591     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.5.1459     Document Type: Article

References (49)

1. Shulman GI: Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176, 2000
2. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J: Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76:149-155, 1985
3. Ryder J, Yang J, Galuska D, Rincon J, Bjornholm M, Krook A, Lund S, Pedersen O, Wallberg-Henriksson H, Zierath J, Holman G: Use of a novel impermeable biotinylated photolabeiing reagent to assess insulin- and hypoxia-stimulated cell surface GLUT4 content in skeletal muscle from type 2 diabetic patients. Diabetes 49:647-654, 2000
4. Koistinen HA, Galuska D, Chibalin AV, Yang J, Zierath JR, Holman GD, Wallberg-Henriksson H: 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes 52:1066-1072, 2003
5. Bjornholm M, Kawano Y, Lehtihet M, Zierath J: Insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal muscle from NlDDM subjects after in vivo insulin stimulation. Diabetes 46:524-627, 1997
6. Kim Y-B, Nikoulina SE, Ciaraldi TP, Henry RR, Kahn BB: Normal insulin-dependent activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 diabetes. J Clin Invest 104:733-741, 1999
7. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarine LJ: Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320, 2000
8. Krook A, Bjornholm M, Galuska D, Jiang X, Fahlman R, Myers M, Wallberg-Henriksson H, Zierath J: Characterization of signal transduction and glucose transport in skeletal muscle from type 2 diabetic patients. Diabetes 49:284-292, 2000
9. Krook A, Roth R, Jiang X, Zierath J, Wallberg-Henriksson H: Insulin-stimulated Akt kinase activity is reduced in skeletal muscle from NIDDM subjects. Diabetes 47:1281-1286, 1998
10. Brozinick JT Jr, Roberts BR, Dohm GL: Defective signaling through Akt-2 and -3 but not Akt-1 in insulin-resistant human skeletal muscle: potential role in insulin resistance. Diabetes 52:935-941, 2003
11. DeFronzo RA, Goodman AM, the Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541-549, 1995
12. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
13. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
14. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL: Efficacy of metformin in type II diabetes; results of a double-blind, placebo-controlled, dose-response trial. Am J Med 103:491-497, 1997
15. Fonseca V, Rosenstock J, Patwardhan R, Salzman A: Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 283:1695-1702, 2000
16. Galuska D, Nolte LA, Zierath JE, Wallberg-Henriksson H: Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 37:826-832, 1994
17. Kumar N, Dey CS: Metformin enhances insulin signalling in insulin-dependent and -independent pathways in insulin resistant muscle cells. Br J Pharmacol 137:329-336, 2002
18. Kim Y-B, Ciaraldi TP, Kong A, Kim D, Chu N, Mohideen P, Mudaliar S, Henry RR, Kahn BB: Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 51:443-448, 2002
19. Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE: Role of skeletal muscle in thiazolidinedione insulta sensitizer (PPAR-γ agonist) action. Endocrinology 139:5034-5041, 1998
20. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective ta patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
21. Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA: Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219, 2001
22. Carey DG, Cowin GJ, Galloway GJ, Jones NP, Richards JC, Biswas N, Doddrell DM: Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 10:1008-1015, 2002
23. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF: The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
24. 3 is defective in muscle ta type 2 diabetes and impaired glucose tolerance: amelioration by rosiglitazone and exercise. Diabetes 52:1926-1934, 2003
25. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA: Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. Diabetes 52:1943-1950, 2003
26. Meyer MM, Levin K, Grimmsmann T, Perwitz N, Eirich A, Beck-Nielsen H, Klein HH: Troglitazone treatment increases protein ktaase B phosphorylation in skeletal muscle of normoglycemic subjects at risk for the development of type 2 diabetes. Diabetes 51:2691-2697, 2002
27. Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA: Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor γ activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277, 2001
28. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M, Sachs JE, Bagchi A, Fridman A, Holder DJ, Doebber TW, Berger J, Elbrecht A, Moller DE, Zhang BB: Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-γ agonists. Endocrinology 143: 2106-2118, 2002
29. Bogacka I, Xie H, Bray GA, Smith SR: The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667, 2004
30. Smith U, Gogg S, Johansson A, Olausson T, Rotter V, Svalstedt B: Thiazolidinediones (PPAR-γ agonists) but not PPARα agonists increase IRS-2 gene expression in 3T3-L1 and human adipocytes. FASEB J 15:215-220, 2001
31. Kane S, Sano H, Liu SCH, Asara JM, Lane WS, Garner CC, Lienhard GE: A method to identify serine kinase substrates: Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 277:22115-22118, 2002
32. Sano H, Kane S, Sano E, Miinea CP, Asara JM, Lane WS, Garner CW, Lienhard GE: Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation. J Biol Chem 278:14599-14602, 2003
33. Zeigerer A, McBrayer MK, McGraw TE: Insulin stimulation of GLUT4 exocytosis, but not its inhibition of endocytosis, is dependent on RabGAP AS160. Mol Biol Cell 10:4406-4415, 2004
34. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, Nuutila P: Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51: 3479-3485, 2002
35. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 15:539-553, 1998
36. Song XM, Ryder JW, Kawano Y, Chibalin AV, Krook A, Zierath JR: Muscle fiber type specificity in insulin signal transduction. Am J Physiol Regul Integr Comp Physiol 277:R1690-1696, 1999
37. Wojtaszewski JF, Hansen BF, Kiens B, Richter EA: Insulin signaling in human skeletal muscle: time course and effect of exercise. Diabetes 46:1775-1781, 1997
38. Karlsson HKR, Zierath JR, Kane S, Krook A, Lienhard GE, Wallberg-Henriksson H: Insulin-stimulated phosphorylation of the Akt substrate AS160 is impaired in skeletal muscle of type 2 diabetic subjects. Diabetes. In press
39. Hundal R, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi S, Schumann W, Petersen K, Landau B, Shulman G: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069, 2000
40. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-873, 1998
41. Petersen K, Krssak M, Inzucchi S, Cline G, Dufour S, Shulman G: Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831, 2000
42. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
43. Virtanen KA, Hallsten K, Parkkola R, Janatuinen T, Lonnqvist F, Viljanen T, Ronnemaa T, Knuuti J, Huupponen R, Lonnroth P, Nuutila P: Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects. Diabetes 52:283-290, 2003
44. Shimokawa T, Kato M, Watanabe Y, Hirayama R, Kurosaki E, Shikama H, Hashimoto S: In vivo effects of pioglitazone on uncoupling protein-2 and -3 mRNA levels in skeletal muscle of hyperglycemic KK mice. Biochem Biophys Res Commum 251:374-378, 1998
45. Ahuja HS, Liu S, Crombie DL, Boehm M, Leibowitz MD, Heyman RA, Depre C, Nagy L, Tontonoz P, Davies PJA: Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents. Mol Pharmacol 59:765-773, 2001
46. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR, Henry RR: Thiazolidinediones upregulates impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285:E354-E362, 2003
47. Yeh J-I, Gulve EA, Rameh L, Birnbaum MJ: The effects of wortmannin on rat skeletal muscle. J Biol Chem 270:2107-2111, 1995
48. Mu J, Brozinick JT, Jr, Valladares O, Bucan M, Birnbaum MJ: A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085-1094, 2001
49. Fryer LGD, Parbu-Patel A, Carling D: The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232, 2002